Author

Robert J. Cardnell

The University of Texas MD Anderson Cancer CenterORCID 0009-0005-6203-0234Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:differential expression· 4 Research Focus:drug response / drug discovery· 4 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:clustering· 1

Frequent Co-Authors

Carl Michael GayiD· 5 shared Lauren A. ByersiD· 5 shared Catherine Allison StewartiD· 4 shared Jing WangiD· 4 shared John Victor HeymachiD· 4 shared Lixia DiaoiD· 4 shared Alejandra G. SerranoiD· 3 shared Bingnan ZhangiD· 3 shared

Activity by Year

2020-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

Carl Michael GayORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 7, 2026

DLL3 expression predicts response and long-term outcome in small cell lung cancer patients treated with tarlatamab

Bingnan Zhang, Lingzhi Hong, Kaiwen Wang…·Lauren A. Byers

This study shows DLL3 expression level predicts response and long-term survival in SCLC patients treated with tarlatamab.

DOI 10.64898/2026.09.03.749238

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 19, 2025

CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level

Mukulika Bose, Cole Ruoff, Shafqat Ehsan…·Loukia Georgiou Karacosta

This study uses CyTOF to profile circulating tumor cells in SCLC patients, identifying subtype-specific markers and treatment response correlations.

2 citations

humanflow cytometry

𝕏 PostBluesky

Cancer BiologyMolecular CancerPeer-reviewedMar 20, 2025

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer

Benjamin B. Morris, Simon Heeke, Yuanxin Xi…·Lauren A. Byers

This study identifies three distinct DDR phenotypes in SCLC associated with chemotherapy response and tumor evolution.

9 citations

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyClinical Cancer ResearchPeer-reviewedAug 16, 2024

YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities

Catherine Allison Stewart, Lixia Diao, Yuanxin Xi…·Carl Michael Gay

25 citationstop 4%

humanbulk RNA-seq

𝕏 PostBluesky

GenomicsbioRxivPreprintJun 30, 2020

Genomic and TCR Repertoire Intratumor Heterogeneity of Small-cell Lung Cancer and its Impact on Survival

Ming Chen, Runzhe Chen, Ying Jin…·Jianjun J. Zhang

This study examines genomic and TCR repertoire heterogeneity in SCLC, finding that lower TCR heterogeneity and mutational burden correlate with better survival.

DOI 10.1101/2020.06.30.180844

humanwhole-exome sequencing

𝕏 PostBluesky